ACP-204 not checked

ACADIA Pharmaceuticals Inc.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2/3 trial completes
Trials
4 active
4 in total · 4 in the EU
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“ACP-204 30 mg given once daily, as capsule OR ACP-204 60 mg given once daily, as capsule”In the company’s words, NCT06194799 on ClinicalTrials.gov
Tested for
Lewy Body Dementia Psychosis (2 trials), Alzheimer's Disease Psychosis (2 trials)
Main trialPhase 3
“A 52-Week, Phase 3, Open-Label Extension Study of ACP-204 in Adults With Lewy Body Dementia Psychosis (LBDP)”In the company’s words, NCT07095465 on ClinicalTrials.gov

Other drugs for Alzheimer's Disease Psychosis

All 3 drugs for Alzheimer's Disease Psychosis

Coming up4

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials4

TrialPhaseCompletesWhat it tests
Phase 3Recruiting Feb 2029 Phase 3, Open Label Extension Study of ACP-204 in Lewy Body Dementia Psychosis
Phase 3Enrolling by invitation Apr 2029 ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension Study
Phase 2/3Recruiting Jan 2028 ACP-204 in Adults With Alzheimer's Disease Psychosis
Phase 2Recruiting Feb 2028 Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia Psychosis
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow ACP-204

Following is part of Solo: you see every change to ACP-204 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in